title: Corticosteroid-induced osteoporosis: an update for dermatologists.
abstract: Long-term corticosteroid treatment is the most common secondary cause of bone loss. Patients treated with long-term corticosteroid therapy may develop osteopenia or osteoporosis, and many have fractures. It is difficult to predict which corticosteroid-treated patients will develop significant skeletal complications because of variability in the underlying diseases treated with corticosteroids, and because of variation in corticosteroid dose over time. Corticosteroid therapy causes an alteration in the ratio between osteoprotegerin (OPG) and receptor activator of nuclear factor κ B (RANK) ligand (RANKL), which leads to early increased bone resorption for the first 3-6 months, with long-term treatment leading primarily to suppression of bone formation. Recently published recommendations advise the use of bisphosphonates or teriparatide in high-risk patients, depending on fracture risk assessed by bone mineral density testing. This article gives an update of current knowledge regarding the pathophysiology, clinical presentation and evaluation, and prevention and treatment of patients with corticosteroid-induced osteoporosis.
authors.affiliation: Mayo Clinic School of Medicine, Rochester, MN, USA. Clarke.Bart@Mayo.edu
authors.forename: Bart L
authors.initials: BL
authors.lastname: Clarke
mesh_terms: D005938:Glucocorticoids / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010006:Osteoblasts / Q000187:drug effects; D010010:Osteoclasts / Q000187:drug effects; D010011:Osteocytes / Q000187:drug effects; D010024:Osteoporosis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D012871:Skin Diseases / Q000188:drug therapy
chemical_list: D005938:Glucocorticoids